Clinical trials: Varices, Esophageal
Esophagogastric Varices, Portal Hypertension
Treatment Outcomes for Portal Hypertension Esophageal and Gastric Varices
This study is a single-center, prospective cohort study based on real-world data. Patients with portal hypertension and esophagogastric varices were enrolled and divided into an endoscopic treatment group and a non-endoscopic…
- Trial name
- NCT07358663
- Where
- China
- Volunteers
- 1,384 people
- Sponsor
- Shanghai Zhongshan Hospital
Portal Hypertension, Cirrhosis
MRI to Assess the Effect of Non-selective Beta-blocker in Patients With Cirrhosis
Background: Standardization and new therapeutic treatments of variceal bleeding has significantly reduced the mortality the last 25 years, but there is still a high 6-week mortality around 15-20% and 1-year mortality of about…
- Conditions
- Portal Hypertension, Cirrhosis, Esophageal Varices, Gastric Varices Bleeding
- Trial name
- NCT03438916
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Hvidovre University Hospital
Portal Hypertension, Liver Cirrhosis
Efficacy and Safety of EUS-Guided Therapy Versus BRTO for Gastric Varices With Shunt
This study is a retrospective, multi-center and observational clinical study. Renmin Hospital of Wuhan University, Beijing Friendship Hospital, Capital Medical University, The fifth medical center of PLA General Hospital…
- Conditions
- Portal Hypertension, Liver Cirrhosis, Gastric Varix, Portosystemic Shunt
- Trial name
- NCT04828369
- Testing
- EUS-guided coil embolization combined with endoscopic cyanoacrylate injection, balloon-occluded retrograde transvenous obliteration
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Renmin Hospital of Wuhan University
Cirrhosis, Portal Hypertension
Danish Carvedilol Study in Portal Hypertension
Patients with large esophageal varices who have not yet experienced bleeding, are normally treated with propranolol, a beta blocking agent that reduces the portal pressure and thereby diminish the risk of bleeding.
- Trial name
- DACAPO (NCT00493480)
- Testing
- carvedilol, propranolol
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Hvidovre University Hospital
Esophageal and Gastric Varices
Carvedilol as an Adjunct to Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding
Gastric variceal obturation is the current endoscopic therapy of choice for gastric variceal bleeding but is associated with a high rebleeding rate. Carvedilol is a potent non-selective β-blocker.
- Trial name
- NCT02504723
- Testing
- carvedilol, cyanoacrylate
- Where
- Taiwan
- Volunteers
- 121 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Esophageal Varices in Cirrhosis of the Liver
Magnetic-assisted Capsule Endoscope With 3D Images in EV Detection in Cirrhotic Patient
Newly development of capsule endoscopy provides a comfortable and minimal invasive modality which is an alternative to conventional esophagogastroduodenoscopy(EGD).
- Trial name
- NCT04588974
- Testing
- magnetic-assisted capsule endoscope system (InsightEyes EGD System) with or without 3D images
- Where
- Taiwan
- Volunteers
- 140 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Liver Cirrhosis, Portal Hypertension
Effect of Administration of Rifaximin on the Portal Pressure of Patients With Liver Cirrhosis and Esophageal Varices
The purpose of this study is to assess whether the add of Rifaximin in patients with liver cirrhosis and esophageal varices treated with a standard therapy with beta blockers, leads to a significant reduction of portal…
- Trial name
- ERASE (NCT02508623)
- Testing
- Rifaximin
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Padova
Esophageal and Gastric Varices, Liver Cirrhosis
Decompression Intervention of Variceal Rebleeding Trial (DIVERT)
The Decompression Intervention of Variceal Rebleeding Trial (DIVERT) is a multi-center prospective randomized clinical trial comparing the radiologic procedure of transjugular intrahepatic portal-systemic shunt (TIPS) with the…
- Trial name
- NCT00006161
- Testing
- Transjugular Intrahepatic Portosystemic Shunt (TIPS), Distal Splenorenal Shunt
- Where
- 5 sites in United States
- Volunteers
- 140 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Gastric Varices, Portal Hypertension
Injection of Cyanoacrylate+Lipiodol vs Cyanoacrylate+Lauromacrogol in Gastric Varices
The purpose of this randomized study to compare effect of endoscopic injection of a mixture of cyanoacrylate and lipiodol versus cyanoacrylate and lauromacrogol in gastric varices.
- Trial name
- NCT01923064
- Testing
- Lipiodol, Lauromacrogol
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Zhongshan Hospital
Cirrhosis, Liver, Portal Hypertension
Carvedilol for Prevention of Esophageal Varices Progression
Carvedilol has been shown to be more potent in decreasing portal hypertension to propranolol. But the efficacy of carvedilol to delay the growth of esophageal varices in chronic hepatitis B patients was unclear.
- Trial name
- Carvedilol (NCT03736265)
- Testing
- Carvedilol
- Where
- 6 sites in China
- Volunteers
- 240 people
- Sponsor
- Beijing Friendship Hospital
Hepatocellular Carcinoma
Comparative Study of Carvedilol Monotherapy Versus Combination Therapy With Endoscopic Variceal Ligation (EVL) for Primary Prophylaxis of Variceal Bleeding in Patients With Hepatocellular Carcinoma With High-Risk Esophageal Varices
Esophageal varices are common in patients with hepatocellular carcinoma (HCC), with an incidence rate of 63% at the time of HCC diagnosis.
- Trial name
- NCT06836778
- Testing
- Carvedilol Tablets, Endoscopic Variceal Ligation
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Esophageal Varices in Cirrhosis of the Liver
HVPG-Guided Therapy Versus EVL Plus NSBB in Second Prophylaxis of Esophageal Variceal Bleeding
A single-center randomized controlled study comparing endoscopic or interventional therapy guided by the hepatic venous pressure gradient (HVPG) , to standard endosopic variceal ligation plus nonselective beta-blocker therapy…
- Trial name
- NCT03687216
- Testing
- HVPG-guided therapy, Routing Therapy
- Where
- China
- Volunteers
- 160 people
- Sponsor
- West China Hospital
Esophageal and Gastric Varices
Clinical Study on Endoscopic Management of GOV1 Esophagogastric Varices
The patients with GOV1 esophagogastric varices will be treated with gastric variceal tissue gel injection, at the same time, the esophageal varices were treated with ligation, sclerotherapy, or no treatment.
- Trial name
- NCT05978752
- Testing
- Endoscopic gel embolization of gastric fundus varices and ligation of esophageal varices, Endoscopic gel embolization of gastric fundus varices and sclerotherapy of esophageal varices, Endoscopic gelatinous embolization of gastric varices (esophageal varices not treated)
- Volunteers
- 57 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Liver Cirrhosis, Gastric Varix
Evaluation of EUS in Preventing Rebleeding After Endoscopic Cyanoacrylate Injection for Gastric Varices
The aim of this study is to explore whether using endoscopic ultrasound (EUS) to assess gastric varices (GV) and giving additional treatment according to the diameter and blood flow of residual after endoscopic cyanoacrylate…
- Conditions
- Liver Cirrhosis, Gastric Varix, Portal Hypertension
- Trial name
- NCT05515861
- Testing
- Endoscopic ultrasound
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Renmin Hospital of Wuhan University
Bleeding Esophageal Varices
Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection
Endoscopic Injection Sclerotherapy vs N-butyl-2-cyanoacrylate Injection
- Trial name
- NCT03388125
- Testing
- Injection Sclerotherapy, N-butyl-2-cyanoacrylate
- Where
- Egypt
- Volunteers
- 113 people
- Sponsor
- Sherief Abd-Elsalam
Portal Hypertension Gastropathy, Esophageal Varices
Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal
This is a multicenter, randomized, double-blind, placebo-controlled study on the effectiveness of treatment with beta-blockers to prevent decompensation of cirrhosis with portal hypertension.
- Conditions
- Portal Hypertension Gastropathy, Esophageal Varices, Spontaneous Bacterial Peritonitis, Hepatic Encephalopathy
- Trial name
- PREDESCI (NCT01059396)
- Testing
- propranolol, carvedilol
- Where
- 8 sites in Spain
- Volunteers
- 201 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Chronic Liver Disease
The SHUNT-V Study for Varices
The purpose of this study is to validate the Disease Severity Index (DSI) from the HepQuant SHUNT Liver Diagnostic Kit (Test) for likelihood of large esophageal varices.
- Trial name
- NCT03583996
- Testing
- HepQuant SHUNT Liver Diagnostic Test
- Where
- 26 sites in United States
- Volunteers
- 306 people
- Sponsor
- HepQuant, LLC
Cirrhosis, Esophageal and Gastric Varices
Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis
The APIXABAN-PK trial is a prospective, randomized, single-blind, placebo-controlled study designed to evaluate the efficacy and safety of apixaban in combination with carvedilol versus placebo with carvedilol in preventing…
- Conditions
- Cirrhosis, Esophageal and Gastric Varices, Ascites, Hepatic Encephalopathy
- Trial name
- APIXABAN-PK (NCT07521332)
- Testing
- Apixaban, Carvedilol
- Where
- Pakistan
- Volunteers
- 220 people
- Sponsor
- Asian Institute Of Medical Sciences
Cirrhosis
Early Primary Prophylaxis of Esophageal Varices
Patients of cirrhosis with portal hypertension aged 18 to 75 years who have small esophageal varices with or without red color signs and have not bled previously will be enrolled.
- Trial name
- NCT01196507
- Testing
- Carvedilol
- Where
- India
- Volunteers
- 140 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Cirrhosis, Portal Hypertension
A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
Endothelin is a human hormone which has been associated with increased portal pressure in patients with liver cirrhosis (also called portal hypertension). Ambrisentan blocks the effects of endothelin.
- Conditions
- Cirrhosis, Portal Hypertension, Ascites
- Trial name
- NCT03827200
- Testing
- Ambrisentan
- Where
- 6 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Noorik Biopharmaceuticals AG